Summit Therapeutics (SMMT) Reports Q3 Loss of GBP0.08/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Summit Therapeutics (SMMT) Remains an Under-the-Radar DMD Play to Watch - Oppenheimer
December 18, 2015 12:57 PM ESTOppenheimer analyst Christopher Marai reiterated an Outperform rating and $28 price target on Summit Therapeutics plc (NASDAQ: SMMT), saying the stock remains an under-the-radar DMD play.
Marai commented, "On 12/17, Summit reported F3Q15 results, ending the quarter with £22.2M in cash. Given its... More
